Stephen T. Oh, MD, PhD

Stephen T. Oh, MD, PhD

Co-Chief and Associate Professor


  • Hematology Division
    Mail Stop 8125-0020-08, Washington University, 660 South Euclid Avenue, St. Louis, MO 63110 (mail)
  • Room 8838 Clinical Sciences Research Building (office)
  • Room 8836 Clinical Sciences Research Building (lab)

Research Interest: Myeloproliferative neoplasms

Research: Myeloproliferative neoplasms (MPNs) are clonal hematologic malignancies typified by genetic alterations that activate JAK-STAT signaling. Chronic MPNs exhibit a propensity for transformation to secondary acute myeloid leukemia (sAML), which carries a dismal prognosis. The overall objective of our work is to better understand the pathogenetic mechanisms responsible for the initiation and development of MPNs, as well as the factors that drive evolution to sAML. We have a particular focus on inflammatory cytokine signaling networks in MPNs. The long-term objective of our work is to translate our laboratory research findings into improved therapies for MPN patients.

For more information, please see Oh Lab



  • 2004-1996: MD, PhD in Cancer Biology, Medical Scientist Training Program, Northwestern University Feinberg School of Medicine, Chicago, IL
  • 1996-1992: AB in Biochemical Sciences (cum laude), Harvard University, Cambridge, MA

Post-Graduate Training

  • 2010-2008: Postdoctoral Fellowship, Stanford University School of Medicine, Stanford, CA
  • 2010-2006: Hematology/Oncology Fellowship, Stanford University School of Medicine, Stanford, CA
  • 2006-2004: Internal Medicine Residency, Stanford University School of Medicine, Stanford, CA

Academic Positions

  • 2021-present: Co-Chief, Division of Hematology
  • 2020-present: Associate Professor of Medicine (Hematology) and Pathology & Immunology, Washington University School of Medicine, St. Louis, MO
  • 2019-2015: Assistant Professor, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO
  • 2019-2010: Assistant Professor, Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO

University & Hospital Appointments & Committees

  • 2014-present: Co-Head, Immunomonitoring Laboratory, Bursky Center for Human Immunology and Immunotherapy Programs (CHiiPs)

Board Certification

  • 2010: American Board of Internal Medicine, Subspecialty Certification in Hematology
  • 2007: American Board of Internal Medicine, DIplomate in Internal Medicine

Honors & Awards

  • 2016: American Society of Hematology Scholar Award
  • 2015: Barnes-Jewish Hospital Foundation/Institute of Clinical and Translational Sciences Pilot Grant
  • 2015: Longer Life Foundation Pilot Grant
  • 2014: BRIGHT Institute Pilot Research Project Award
  • 2014: Doris Duke-Damon Runyon Clinical Investigator Award
  • 2013: Central Society for Clinical Research Early Career Development Award
  • 2013: Barnes-Jewish Hospital Foundation/Institute of Clinical and Translational Sciences Pilot Grant
  • 2013: Burroughs Wellcome Fund Collaborative Research Travel Grant
  • 2012: NHLBI K08 Mentored Clinical Scientist Research Career Development Award
  • 2011: Sidney Kimmel Foundation Scholar Award
  • 2011: American Cancer Society Institutional Research Grant. Siteman Cancer Center, Washington University School of Medicine
  • 2011: American Society of Clinical Oncology Young Investigator Award
  • 2011: Leukemia Research Foundation New Investigator Award
  • 2011: NHLBI K12 Heme Scholar Award
  • 2010: American Association for Cancer Research GlaxoSmithKline Outstanding Clinical Scholar Award. AACR Annual Meeting, Washington, DC
  • 2010: American Association for Cancer Research Aflac, Inc. Scholar-in-Training Award. AACR Translational Cancer Medicine Meeting, San Francisco, CA
  • 2010: American Society of Hematology Travel Award. ASH Annual Meeting, Orlando, FL
  • 2009: Stanford Cancer Center Developmental Cancer Research Award. Co-investigator; PI: Gotlib
  • 2009: NIH Loan Repayment Program Award
  • 2008: Best Poster Award, Stanford Hematology and Oncology Divisions Annual Research Retreat, Pacific Grove, CA
  • 2001: Gramm Travel Fellowship Award, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
  • 2001: Student Fellowship, 19th International Papillomavirus Conference, Florianopolis, Brazil
  • 2000: Student Fellowship, 18th International Papillomavirus Conference, Barcelona, Spain

Editorial Boards

  • 2017-present: JCO Precision Oncology
  • 2010-present: Therapeutic Advances in Hematology

Panels & Committees

  • 2021-present: Consortium Management Board Member, NIDDK Hematology Centers Program
  • 2015-present: Myeloproliferative Neoplasms Committee Member, National Comprehensive Cancer Network
  • 2013-present: Study Section Member, American Cancer Society Institutional Research Grant, Siteman Cancer Center
  • 2021-2017: Ad hoc Reviewer, Siteman Investment Program, Siteman Cancer Center
  • 2020: Ad hoc Reviewer, Longer Life Foundation Grant Program
  • 2020: Ad hoc Reviewer, NIDDK U54 Cooperative Centers of Excellence in Hematology
  • 2019: Ad hoc Reviewer, KL2 Career Development Program, Washington University
  • 2019: Ad hoc Reviewer, Florida Department of Health Florida Department of Health Bankhead-Coley Cancer Research Program
  • 2019: Ad hoc Reviewer, MPN Research Foundation Challenge Grant Program
  • 2018: Ad hoc Reviewer, Live Like Bella Pediatric Cancer Research Initiative
  • 2018: Ad hoc Reviewer, Wellcome Trust Equipment Grant Program
  • 2018: Ad hoc Reviewer, Bloodwise Grant Program
  • 2017: Ad hoc Reviewer, National Fellowships for Graduate Women in Science
  • 2016: Ad hoc Reviewer, Wellcome Trust Clinical Research Career Development Fellowship

Professional Societies & Organizations

  • 2006-present: American Society of Hematology

Selected Publications

  • DUSP6 Mediates Resistance to JAK2 Inhibition and Drives Leukemic Progression
    Kong T, Laranjeira ABA, Yang K, Fisher DAC, Yu L, Poittevin De La Fregonniere L, Wang AZ, Ruzinova MB, Fowles JS, Fulbright MC, Cox MJ, Celik H, Challen GA, Huang S, Oh ST
    Nat Cancer 2023 Jan;4(1):108-127
  • A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms
    Celik H, Krug E, Zhang CR, Han W, Issa N, Koh WK, Bjeije H, Kukhar O, Allen M, Li T, Fisher DAC, Fowles JS, Wong TN, Stubbs MC, Koblish HK, Oh ST, Challen GA
    Cancer Discov 2021 Dec 1;11(12):3126-3141
  • Pevonedistat Targets Malignant Cells in Myeloproliferative Neoplasms in Vitro and in Vivo Via NFkappaB Pathway Inhibition
    Kong T, Laranjeira ABA, Collins TB, De Togni ES, Wong AJ, Fulbright MC, Ruzinova M, Celik H, Challen GA, Fisher DAC, Oh ST
    Blood Adv 2022 Jan 25;6(2):611-623
  • Cytokine Production in Myelofibrosis Exhibits Differential Responsiveness to JAK-STAT, MAP Kinase, and NFkappaB Signaling
    Fisher DAC, Miner CA, Engle EK, Hu H, Collins TB, Zhou A, Allen MJ, Malkova ON, Oh ST
    Leukemia 2019 Aug;33(8):1978-1995
  • Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms
    He F, Laranjeira AB, Kong T, Lin S, Ashworth KJ, Liu A, Lasky NM, Fisher DA, Cox MJ, Fulbright MC, Antunes-Heck L, Yu L, Brakhane M, Gao B, Sykes SM, D’Alessandro A, Di Paola J, Oh ST.
    J Clin Invest. 2024 Feb 1;134(3):e172256. doi: 10.1172/JCI172256